Terms: = Ovarian cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Prognosis
90 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells.
Kim ES; Kim S; Moon A
Oncol Res; 2023; 31(6):867-875. PubMed ID: 37744269
[TBL] [Abstract] [Full Text] [Related]
3. Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2-AS2/MEK/erk/STAT3 signaling.
Ling L; Wen Y; Xiong Y; Liu X; Chen J; Liu T; Zhang B
J Gene Med; 2024 Jan; 26(1):e3571. PubMed ID: 37483091
[TBL] [Abstract] [Full Text] [Related]
4. HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/erk signaling pathway.
Ma H; Qi G; Han F; Gai P; Peng J; Kong B
Cell Commun Signal; 2023 Jun; 21(1):144. PubMed ID: 37328851
[TBL] [Abstract] [Full Text] [Related]
5. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Cheng F; Hansson VC; Georgolopoulos G; Mani K
Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
[TBL] [Abstract] [Full Text] [Related]
6. Serum Exosomes From Epithelial ovarian cancer Patients Contain LRP1, Which Promotes the Migration of Epithelial ovarian cancer Cell.
Zhou W; Ma J; Zhao H; Wang Q; Guo X; Chen L; Cao Z; Xu J; Zhang B; Zhou X
Mol Cell Proteomics; 2023 Apr; 22(4):100520. PubMed ID: 36842607
[TBL] [Abstract] [Full Text] [Related]
7. FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer.
Zhu W; Huang M; Thakur A; Yan Y; Wu X
PeerJ; 2023; 11():e14827. PubMed ID: 36751636
[TBL] [Abstract] [Full Text] [Related]
8. Disruption of ovarian cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase.
Lazo JS; Isbell KN; Vasa SA; Llaneza DC; Rastelli EJ; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2023 Mar; 384(3):429-438. PubMed ID: 36627205
[TBL] [Abstract] [Full Text] [Related]
9. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/erk/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract] [Full Text] [Related]
10. Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κB and TGF-β2 signaling.
Lin SC; Liao YC; Chen PM; Yang YY; Wang YH; Tung SL; Chuang CM; Sung YW; Jang TH; Chuang SE; Wang LH
J Biomed Sci; 2022 Dec; 29(1):109. PubMed ID: 36550569
[TBL] [Abstract] [Full Text] [Related]
11. HERPUD1 promotes ovarian cancer cell survival by sustaining autophagy and inhibit apoptosis via PI3K/AKT/mTOR and p38 MAPK signaling pathways.
Nie X; Liu D; Zheng M; Li X; Liu O; Guo Q; Zhu L; Lin B
BMC Cancer; 2022 Dec; 22(1):1338. PubMed ID: 36544104
[TBL] [Abstract] [Full Text] [Related]
12. ALG3 Promotes Peritoneal Metastasis of ovarian cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.
Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
[TBL] [Abstract] [Full Text] [Related]
13. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract] [Full Text] [Related]
14. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract] [Full Text] [Related]
15. Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.
Xu C; Minaguchi T; Qi N; Fujieda K; Suto A; Itagaki H; Shikama A; Tasaka N; Akiyama A; Nakao S; Ochi H; Satoh T
World J Surg Oncol; 2022 Apr; 20(1):139. PubMed ID: 35490254
[TBL] [Abstract] [Full Text] [Related]
16. Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial ovarian cancer Through the p38 MAPK Pathway.
Gao J; Zhu L; Zhuang H; Lin B
Adv Ther; 2022 Jan; 39(1):360-378. PubMed ID: 34739698
[TBL] [Abstract] [Full Text] [Related]
17. Dysfunction of miR-802 in tumors.
Gao T; Zou M; Shen T; Duan S
J Clin Lab Anal; 2021 Nov; 35(11):e23989. PubMed ID: 34558723
[TBL] [Abstract] [Full Text] [Related]
18. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
[TBL] [Abstract] [Full Text] [Related]
19. Determination of Potential Therapeutic Targets and Prognostic Markers of ovarian cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract] [Full Text] [Related]
20. GPBAR1 Promotes Proliferation of Serous ovarian cancer by Inducing Smad4 Ubiquitination.
Li H; Zhao J; Shi X
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):519-526. PubMed ID: 33605573
[TBL] [Abstract] [Full Text] [Related]
[Next]
